Completed
Anti-MAG First Administration to Human
NCT00622609
- Conditions
- Brain Diseases, Cardiovascular Diseases, Central Nervous System Diseases, +5 more
- Locations
-
- GSK Investigational Site Baltimore, Maryland, United States
- GSK Investigational Site Randwick, Sydney, New South Wales, Australia